Epidemiological Profile Of 175 Patients With Crohn's Disease Submitted To Biological Therapy

Introduction: There is currently an increasing use of biological agents in the management of Crohn's disease (CD). There is lack of data regarding the epidemiological profile of patients on infliximab (IFX) and adalimumab (ADA) for CD in Brazil. Objective: To identify the epidemiological characteristics of patients with CD who underwent biological therapy. Method: Retrospective multicenter study, with CD patients on biological therapy. Analyzed variables: gender, age at treatment initiation, Montreal classification, concomitant perianal disease and smoking status. Results: 175 patients without previous exposure to biological agents were included, 93 (53%) were male. The mean age at treatment initiation was 35.5 (2-79) years old an the mean disease duration was 46.9 (0-480) months. Overall, 117 (66.9%) patients used IFX and 58 (33.1%), ADA. Montreal classification: age at diagnosis - A1 (n=21; 12%), A2 (n=102; 58.3%), and A3 (n=52; 29.7%). CD location - L1 (n=42; 24%), L2 (n=51; 29.1%), L3 (n=81; 46.3%), and L4 (n=1, 0.6%). Phenotype -B1 (n=59; 33.7%), B2 (n=46; 26.3%), and B3 (n=70; 40%). Perianal disease was found in 89 (50.9%) patients. Conclusions: The epidemiological profile of patients was similar to the literature. There was a high prevalence of patients with fistulizing CD.324395401Colombel, J.F., Sandborn, W.J., Reinisch, W., Mantzaris, G.J., Kornbluth, A., Rachmilewitz, D., Infliximab, azathioprine, or combination therapy for Crohn's disease (2010) N Engl J Med, 362 (15), pp. 1383-1395Souza, M.H.L.P., Troncon, L.E.A., Rodrigues, C.M., Viana, C.F.G., Onofre, P.H.C., Monteiro, R.A., Evolução da ocorrência (1980-1999) da doença de Crohn e da retocolite ulcerativa idiopática e análise das suas características clínicas em um hospital universitário do sudeste do Brasil (2002) Arq Gastroenterol, 39 (2), pp. 98-105Sedlack, R.E., Whisnant, J., Elveback, L.R., Kurland, L.T., Incidence of Crohn's disease in Olmsted County, Minnesota, 1935-1975 (1980) Am J Epidemiol, 112 (6), pp. 759-763Sonnenberg, A., Geographic variation in the incidence of and mortality from inflammatory bowel disease (1986) Dis Colon Rectum, 29 (12), pp. 854-861Yanai, H., Hanauer, S.B., Assessing response and loss of response to biological therapies in IBD (2011) Am J Gastroenterol, 106 (4), pp. 685-698Chaparro, M., Panés, J., García, V., Merino, O., Nos, P., Domènech, E., Long-term durability of response to adalimumab in Crohn's disease (2012) Inflamm Bowel Dis, 18 (4), pp. 685-690Rutgeerts, P., van Assche, G., Vermeire, S., Optimizing anti-TNF treatment in inflammatory bowel disease (2004) Gastroenterology, 126 (6), pp. 1593-1610Wu, E.G., Mulani, P.M., Yu, A.P., Tang, J., Pollack, P.F., Loss of treatment response to infliximab maintenance therapy in Crohn's disease: A payor perspective (2008) Value Health, 11 (5), pp. 820-829Dignass, A., van Assche, G., Lindsay, J.O., Lémann, M., Söderholm, J., Colombel, J.F., The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management (2010) J Crohns Colitis, 4 (1), pp. 28-62Silverberg, M.S., Satsangi, J., Ahmad, T., Arnott, I.D., Bernstein, C.N., Brant, S.R., Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology (2005) Can J Gastroenterol, 19 (SUPPL. A), pp. 5-36Panaccione, R., Loftus, E.V., Binion, D., McHugh, K., Alam, S., Chen, N., Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial (2011) Can J Gastroenterol, 25 (8), pp. 419-425Colombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R., Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial (2007) Gastroenterology, 132 (1), pp. 52-65Lichtiger, S., Binion, D.G., Wolf, D.C., Present, D.H., Bensimon, A.G., Wu, E., The CHOICE trial: Adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy (2010) Aliment Pharmacol Ther, 32 (10), pp. 1228-1239Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F., Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial (2002) Lancet, 359 (9317), pp. 1541-1549Sands, B.E., Anderson, F.H., Bernstein, C.N., Chey, W.Y., Feagan, B.G., Fedorak, R.N., Infliximab maintenance therapy for fistulizing Crohn's disease (2004) N Engl J Med, 350 (9), pp. 876-885Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., van Assche, G., Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: Results from a single-centre cohort (2009) Gut, 58 (4), pp. 492-500Cosnes, J., Gower-Rousseau, C., Seksik, P., Cortot, A., Epidemiology and natural history of inflammatory bowel diseases (2011) Gastroenterology, 140 (6), pp. 1785-1794Kotze, P.G., Vieira, A., Sobrado, C.W., Salem, J.B., Kotze, L.M.S., Adalimumab in the induction of Crohn's disease remission: Results of a Brazilian multicenter case series (2011) J Coloproctol, 31 (3), pp. 233-240Poli, D.D., (2007) Aspectos Da Raça E Da Ancestralidade Na Apresentação E Evolução Da DC No Brasil [Dissertação De Mestrado], p. 51. , São Paulo: Faculdade de Medicina da Universidade de São PauloSouza, M.M., Belasco, A.G.S., Aguilar-Nascimento, J.E., Perfil epidemiológico dos pacientes portadores de doença inflamatória intestinal do estado de Mato Grosso (2008) Rev Bras Colo-proctol, 28 (3), pp. 324-328Teixeira, M.G., Habr-Gama, A., Takiguti, C.K., Brunetti, N.C., Pinotti, H.W., Aspectos epidemiológicos da doença de Cröhn em 140 pacientes do serviço de Colo-Proctologia do HCFMUSP (1993) Rev Bras Colo-Proctol, 13 (4), pp. 128-13